Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RPA1 | P27694 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590067 | 0.76 | RAB9A (0.38) | LMNANPC1RAB9ANOTUMPOLB | |
| SCHEMBL2764416 | 0.76 | TDP1 (0.38) | LMNACYP2A6NPC1RAB9ANOTUM | |
| SCHEMBL9465254 | 0.73 | MKNK1 (0.41) | — | |
| SCHEMBL9467462 | 0.73 | CNR2 (0.37) | NPC1RAB9AKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL1436626 | 0.71 | CA12 (0.46) | LMNANPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL6028317 | 0.70 | PIM1 (0.49) | LMNATP53TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL9465257 | 0.67 | CYP2A6 (0.41) | CYP2A6 | |
| SCHEMBL293609 | 0.67 | CYP2A6 (0.41) | LMNACYP2A6NPC1RAB9ANOTUM | |
| SCHEMBL9465377 | 0.67 | LPL (0.33) | CYP1A2LMNAKDM4EHSD17B10 | |
| SCHEMBL28215 | 0.66 | CYP1A2 (0.73) | CYP1A2LMNACYP2A6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | claimed |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | claimed |
| CN-101528748-A | Imidazopyridazines as PI3K lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-09-09 | — | — | CN | claimed |
| EP-2079744-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | claimed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | claimed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | claimed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| CN-109776537-B | Purine diones as WNT pathway modulators | 新加坡科技研究局 | 2021-12-14 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-11-24 | — | — | US | disclosed |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-18 | — | — | US | disclosed |
| CN-1699347-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2005-11-23 | — | — | CN | disclosed |
| CN-1495170-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | G.D.ɪ����˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1134418-C | Substituted pyrazolyl benzenesulfonamides for treating inflammation | - | 2004-01-14 | — | — | CN | disclosed |
| CN-1127484-C | Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation | SEARLE & CO (US) | 2003-11-12 | — | — | CN | disclosed |
| CN-1280125-A | Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation | SEARLE & CO (US) | 2001-01-17 | — | — | CN | disclosed |
| CN-1280126-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2001-01-17 | — | — | CN | disclosed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | CYP1A2 452/4885LMNA 2103/4885CYP2A6 527/4885 |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | CYP1A2 144/4885LMNA 2300/4885CYP2A6 264/4885 |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | PI4KA, PIK3CA, PIK3CB | CYP1A2 774/4885LMNA 3641/4885CYP2A6 1031/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | CYP1A2 452/4885LMNA 2103/4885CYP2A6 527/4885 |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | CYP1A2 144/4885LMNA 2300/4885CYP2A6 264/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | CYP1A2 452/4885LMNA 2103/4885CYP2A6 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.